NICE Backs New Targeted Therapy for Advanced Cervical Cancer Edited by Zeel Mehta Medscape UK May 22, 2026

https://www.medscape.com/viewarticle/nice-backs-new-targeted-therapy-advanced-cervical-cancer-2026a1000gmb The National Institute for Health and Care Excellence (NICE) has recommended tisotumab vedotin (Tivdak, Genmab) as an option for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment in adults.